On September 27th, Dagewei Kang (301126.SZ) announced that, in order to further meet the needs of its global strategy and enhance the company's market competitiveness, the company used its own funds to set up a wholly-owned subsidiary, Hunan Dagewei Kang Regenerative Medicine Research Institute Co., Ltd. (hereinafter referred to as "Dagewei Kang Regenerative Medicine Research Institute"). Recently, the Dagewei Kang Regenerative Medicine Research Institute has completed the industrial and commercial registration and obtained the "Business License" issued by the Changsha County Market Supervision Administration.

The establishment of a wholly-owned subsidiary this time is conducive to further strengthening the company's development in the medical services sector, enhancing the company's basic research and applied research capabilities in this field, realizing the company's technological reserves in this field, and transforming related research results. At the same time, it also provides support for the company to cultivate professional talents in related fields and diversified development, effectively enhancing the company's sustainable development capabilities and overall competitiveness. This strategic layout is expected to efficiently coordinate the company's subsidiary (Changsha Jiachen Reproductive and Genetic Specialized Hospital Co., Ltd.) in the medical services sector, helping the company better grasp the development opportunities of the medical health industry, consolidate its market position, and provide customers with more comprehensive and high-quality services.